Takeda Shire Cooperation Agreement

Takeda (Media – outside Japan) Elissa JohnsenElissa.Johnsen@takeda.com-1 312 285 3203 Tsuyoshi TadaTsuyoshi.Tada@takeda.com -1 617 551 2933 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global sector, The research and development-focused pharmaceutical company, which is committed to improving the health and future of patients by translating science into life-changing drugs. Takeda focuses its research and development efforts on oncology, gastroenterological and neuroscientific therapies as well as vaccines. Takeda conducts research and development both internally and with partners to stay on the cutting edge of innovation. Innovative products, particularly in oncology and gastroenterology, as well as Takeda`s presence in emerging countries are currently fuelling Takeda`s growth. Approximately 30,000 Takeda employees are committed to improving the quality of life for patients and collaborate with Takeda`s healthcare partners in more than 70 countries. For more information, see www.takeda.com/newsroom/. Takeda (Media – Inside Japan) Kazumi Kobayashikazumi.kobayashi@takeda.com-81 3 3278 2095 Takeda (Investor Relations) Takashi Okubotakeda.ir.contact@takeda.com-81 3 3278 2306 In accordance with Article 26 of the City Code on Takeovers and Mergers, a copy of the JBIC loan will be published on the takedas website and www.takeda.com/investors/offer-for-shire the following day of the announcement. Please note that the acquisition remains subject to certain conditions, including the agreement of the shareholders of both companies. When two or more persons, on the basis of a formal or informal agreement, act together to acquire or control a stake in relevant securities of an offering company or a securities supplier, they are considered to be a single person within the meaning of Rule 8.3. Publication on the website In accordance with Rule 26.1 of the Code, a copy of this notice (subject to certain restrictions on persons residing in restricted jurisdictions) will be made available on Takeda`s website in www.takeda.com/investors/offer-for-shire no later than 12:00 p.m. (London time) on the business day following the date of this announcement. The content of the website mentioned in this notice is not part of this ad and is not part of this announcement.

While Japan`s Fair Trade Commission approved the agreement last October, the British court sanctioned it on 3 January this year. Takeda shareholders agreed to the deal last month. . The new agreement with Evotec is likely related to Takeda`s need to expand its pipeline and generate new revenue streams to pay off debts it incurred under the Shire agreement. Evotec and Takeda have already collaborated on the development of Alzheimer`s disease. IFRS 9 Depreciation How this affects your business and how we can help them. . “Working with first-class partners in drug discovery such as Evotec is critical to our model of transformative drug discovery and development,” says Steve Hitchcock, Global Head of Research at Takeda.

“Takeda has been working with Evotec for a long time and is confident in Evotec`s capabilities.” The regulator added that the developments constituted “exceptional circumstances” that rendered the transfer of SHP647 unnecessary. Takeda said the acquisition offers an increased geographic presence and position in Japan and the United States. The company will be able to supply about 80 countries or regions. . Shares have fallen about 20% since the agreement was first released in April, but rose 2% on Tuesday after the deal was confirmed in a statement. . Under the terms of the agreement, Takeda Evotec pays a one-time premium to access Evotec technology.

カテゴリー: 未分類 | 投稿者: